<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1207">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353271</url>
  </required_header>
  <id_info>
    <org_study_id>[1582736-1]</org_study_id>
    <nct_id>NCT04353271</nct_id>
  </id_info>
  <brief_title>Trial of Hydroxychloroquine In Covid-19 Kinetics</brief_title>
  <acronym>THICK</acronym>
  <official_title>A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Alabama</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test if the medication Hydroxychloroquine will decrease the amount of virus(as measured by
      PCR) , 7 days after initiation of therapy compared to control patients receiving placebo.

      The study design is a randomized (5 days of medication v. 5 days of placebo) clinical trial
      initiated immediately after diagnosis in ambulatory health care workers at University of
      South Alabama Health, or in ambulatory USA patients. At 7 days after enrollment another
      nasopharyngeal swab will be taken to measure if the virus is still present. At 10 weeks we
      will measure immunity from Covid-19 using a single blood sample. It is a phase 2/3 clinical
      trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydroxychloroquine (HCQ), which is a less toxic derivative of chloroquine (CQ), has been
      shown to be effective in inhibiting Covid-19 infection in vitro. The evidence from clinical
      research trials is sparse and has many flaws. Much of the Chinese experience with Chloroquine
      comes from a letter to the editor and a news briefing/conference held on February 15, 2020.
      The letter describes experience with more than 100 patients treated with CQ in multicenter
      clinical trials but the letter provides no quantitative data to back their claims. At least
      one non-randomized clinical trial has been performed in Europe. Covid-19 infected patients
      received 10 days of HCQ daily and underwent daily testing of viral loads from nasopharyngeal
      swabs. The subjects receiving HCQ were much more likely (P&lt;0.02) to clear their viral load
      than subjects who did not receive HCQ. The study had many flaws, which make the conclusions
      less valuable than rigorously designed randomized clinical trial. This study is designed as a
      randomized, blinded trial to either confirm or refute the efficacy of HCQ in early treatment
      of Covid19 infection to ameliorate disease severity, and reduce viral load.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    FDA recommendations to not use outside of the hospital setting or in a clinical trial due to
    the risk of cardiac arrhythmias
  </why_stopped>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Actual">July 8, 2020</completion_date>
  <primary_completion_date type="Actual">July 8, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo verses medication clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded to subject and investigators</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of virus free subjects</measure>
    <time_frame>7 days after initiation of trial</time_frame>
    <description>Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease severity</measure>
    <time_frame>6 days</time_frame>
    <description>Participants will self-report disease severity status as one of the following 5 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization (score of 3), or Covid 19 with care requiring hospitalization (score of 4), or Covid 19 with death (Score of 5) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalization</measure>
    <time_frame>14 days</time_frame>
    <description>Number of subjects in each arm who are hospitalized for Covid 19 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>70 Days (10 weeks)</time_frame>
    <description>Number of subjects in each arm who die secondary to Covid-19 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of confirmed SARS-CoV-2 Detection</measure>
    <time_frame>14 days</time_frame>
    <description>Number of subjects in each arm who have confirmed Covid-19 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause study medication discontinuation or withdrawal</measure>
    <time_frame>14 days</time_frame>
    <description>Number of subjects in each arm who discontinue or withdraw medication use for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunity to Covid-19</measure>
    <time_frame>70 days (10 weeks)</time_frame>
    <description>Blood tests to determine level of immunity in each subject</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Covid 19</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive the study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will take placebo for 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms occurring within 3 days prior to patient presenting to USA Facility for PCR
             nasopharyngeal swab

          -  Nasopharyngeal swab positive for Covid-19 infection and/or exposure and/or symptoms
             congruent with fever and cough

          -  Male or Female age 19 to 89 years

          -  Able to take oral medications

          -  Patients not requiring hospitalization

          -  Provision of informed consent

        Exclusion Criteria:

          -  Known history of EKG QTc prolongation abnormality

          -  Contraindication or allergy to hydroxychloroquine

          -  Retinal eye disease

          -  Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency

          -  Known chronic kidney disease, stage 4 or 5 or receiving dialysis

          -  Weight &lt; 40 kg

          -  Current use of: hydroxychloroquine or cardiac medicines of: flecainide, Tambocor;
             amiodarone, Cordarone, Pacerone; digoxin or Digox, Digitek, Lanoxin; procainamide or
             Procan, Procanbid, propafenone, Rythmal)

          -  Known hepatic disease (cirrhosis, hepatitis)

          -  Active treatment for cancer (chemotherapy, radiation, surgery within 3 months

          -  On immunosuppressive drugs steroids, antirejection medications.

          -  Recipient of solid organ transplant

          -  Pregnancy/breastfeeding

          -  Past medical history Porphyria (may exacerbate disease)

          -  PMH Psoariasis (can worsen disease)

          -  No access to internet or email

          -  Current suicidal thoughts according to Columbia scale

          -  In the screening process before signing consent, subjects will be asked if they are
             suicidal. If this response is yes, patients will be excluded from trial and directed
             to the National Suicide Prevention Lifeline: 1-800-273-8255.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William O Richards, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Alabama College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Percival I. Nuclear winter. Practitioner. 1988 Feb 8;232(1442):140-1.</citation>
    <PMID>3217330</PMID>
  </reference>
  <reference>
    <citation>Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.</citation>
    <PMID>32074550</PMID>
  </reference>
  <reference>
    <citation>Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.</citation>
    <PMID>32194981</PMID>
  </reference>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <reference>
    <citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.</citation>
    <PMID>32150618</PMID>
  </reference>
  <reference>
    <citation>Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020 Apr;55(4):105945. doi: 10.1016/j.ijantimicag.2020.105945. Epub 2020 Mar 17.</citation>
    <PMID>32194152</PMID>
  </reference>
  <reference>
    <citation>Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.</citation>
    <PMID>32145363</PMID>
  </reference>
  <reference>
    <citation>Stokkermans TJ, Trichonas G: Chloroquine And Hydroxychloroquine Toxicity. In: StatPearls. edn. Treasure Island (FL); 2020.</citation>
  </reference>
  <reference>
    <citation>Baden LR, Rubin EJ. Covid-19 - The Search for Effective Therapy. N Engl J Med. 2020 May 7;382(19):1851-1852. doi: 10.1056/NEJMe2005477. Epub 2020 Mar 18.</citation>
    <PMID>32187463</PMID>
  </reference>
  <reference>
    <citation>Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. doi: 10.1093/jac/dkaa114.</citation>
    <PMID>32196083</PMID>
  </reference>
  <reference>
    <citation>Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am J Chin Med. 2020;48(3):737-762. doi: 10.1142/S0192415X20500378. Epub 2020 Mar 13. Review.</citation>
    <PMID>32164424</PMID>
  </reference>
  <reference>
    <citation>Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.</citation>
    <PMID>32147628</PMID>
  </reference>
  <reference>
    <citation>Beigelman A, Bacharier LB, Baty J, Buller R, Mason S, Schechtman KB, Sajol G, Isaacson-Schmid M, Castro M, Storch GA. Does azithromycin modify viral load during severe respiratory syncytial virus bronchiolitis? J Allergy Clin Immunol. 2015 Oct;136(4):1129-31. doi: 10.1016/j.jaci.2015.06.011. Epub 2015 Jul 26.</citation>
    <PMID>26215052</PMID>
  </reference>
  <reference>
    <citation>Jiang S. Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. 2020 Mar;579(7799):321. doi: 10.1038/d41586-020-00751-9.</citation>
    <PMID>32179860</PMID>
  </reference>
  <reference>
    <citation>Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R: Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls. edn. Treasure Island (FL); 2020.</citation>
  </reference>
  <reference>
    <citation>Fedson DS, Opal SM, Rordam OM. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. mBio. 2020 Mar 20;11(2). pii: e00398-20. doi: 10.1128/mBio.00398-20.</citation>
    <PMID>32198163</PMID>
  </reference>
  <reference>
    <citation>Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. Arthritis Rheumatol. 2020 Mar;72(3):448-453. doi: 10.1002/art.41121. Epub 2020 Jan 7.</citation>
    <PMID>31532077</PMID>
  </reference>
  <reference>
    <citation>Sun ML, Yang JM, Sun YP, Su GH. [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222. doi: 10.3760/cma.j.issn.1001-0939.2020.03.016. Chinese.</citation>
    <PMID>32164092</PMID>
  </reference>
  <reference>
    <citation>Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. Ann Intensive Care. 2020 Mar 18;10(1):33. doi: 10.1186/s13613-020-00650-2.</citation>
    <PMID>32189136</PMID>
  </reference>
  <reference>
    <citation>FitzGerald GA. Misguided drug advice for COVID-19. Science. 2020 Mar 27;367(6485):1434. doi: 10.1126/science.abb8034. Epub 2020 Mar 20.</citation>
    <PMID>32198292</PMID>
  </reference>
  <reference>
    <citation>Lotery A, Burdon M. Monitoring for hydroxychloroquine retinopathy. Eye (Lond). 2020 Aug;34(8):1301-1302. doi: 10.1038/s41433-020-0795-2. Epub 2020 Feb 13.</citation>
    <PMID>32055019</PMID>
  </reference>
  <reference>
    <citation>Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.</citation>
    <PMID>32171740</PMID>
  </reference>
  <reference>
    <citation>Sivakumar GK, Liu J, Sokoluk C, Ing EB. Online calculator for hydroxychloroquine dosing. Can J Ophthalmol. 2020 Aug;55(4):e148-e150. doi: 10.1016/j.jcjo.2020.01.002. Epub 2020 Feb 18.</citation>
    <PMID>32081373</PMID>
  </reference>
  <reference>
    <citation>Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Review.</citation>
    <PMID>32169119</PMID>
  </reference>
  <reference>
    <citation>Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, Yu W, Zhang J. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020 Jun;95:183-191. doi: 10.1016/j.ijid.2020.03.013. Epub 2020 Mar 12.</citation>
    <PMID>32173576</PMID>
  </reference>
  <reference>
    <citation>Glauser W. Proposed protocol to keep COVID-19 out of hospitals. CMAJ. 2020 Mar 9;192(10):E264-E265. doi: 10.1503/cmaj.1095852.</citation>
    <PMID>32152059</PMID>
  </reference>
  <reference>
    <citation>Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020 Apr;55(4):105944. doi: 10.1016/j.ijantimicag.2020.105944. Epub 2020 Mar 13.</citation>
    <PMID>32179150</PMID>
  </reference>
  <reference>
    <citation>Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020 Mar 16;24(1):91. doi: 10.1186/s13054-020-2818-6.</citation>
    <PMID>32178711</PMID>
  </reference>
  <reference>
    <citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.</citation>
    <PMID>32187464</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Alabama</investigator_affiliation>
    <investigator_full_name>William Richards</investigator_full_name>
    <investigator_title>Professor and Chair Surgery</investigator_title>
  </responsible_party>
  <keyword>covid 19</keyword>
  <keyword>plaquenil</keyword>
  <keyword>hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

